[1]鲁毅,贾奕扬,段靖,等.环维黄杨星D新型纳米递药系统的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(5):524-527.[doi:10.3969/j.issn.1672-271X.2022.05.016]
　LU Yi,JIA Yi-yang,DUAN Jing,et al.Recent progress of novel nano-drug delivery system of Cyclovirobuxine D[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(5):524-527.[doi:10.3969/j.issn.1672-271X.2022.05.016]

点击复制

环维黄杨星D新型纳米递药系统的研究进展()

分享到62.8K

参考文献/References:

[1]陈聪地, 杜琳, 王洁雪, 等. 黄杨宁及其衍生物的研究进展[J]. 山东化工, 2020, 49(8): 82-86.
[2]梁秉文, 邓晨安, 王学斌, 等. 黄杨木碱Ⅰ、Ⅱ、Ⅲ、Ⅳ的分离与结构研究[J]. 中国药学杂志, 1981, 16: 3-4.
[3]柯仲成, 桂双英, 虞盛舟, 等. 黄杨宁的研究进展[J]. 甘肃中医学院学报, 2011, 28(1): 71-73.
[4]黄丹丹, 许立. 环维黄杨星D心血管系统药理作用研究进展[J]. 贵阳中医学院学报, 2013, 35(1): 241-243.
[5]Wu JB, Zhou Y, Liang CL, et al. Cyclovirobuxinum D alleviates cardiac hypertrophy in hyperthyroid rats by preventing apoptosis of cardiac cells and inhibiting the p38 mitogen-activated protein kinase signaling pathway[J]. Chin J Integr Med, 2017, 23(10): 770-778 .
[6]Jiang ZH, Fu LY, Xu YN, et al. Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses[J]. Sci Rep, 2020, 10(1): 6427.
[7]Guo Q, Guo JB, Yang R, et al. Cyclovirobuxine D attenuates doxorubicin-induced cardiomyopathy by suppression of oxidative damage and mitochondrial biogenesis impairment[J]. Oxid Med Cell Longev, 2015, 2015: 151972.
[8]Lu J, Sun DP, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells[J]. J Pharmacol Sci, 2014, 125(1): 74-82.
[9]Wu J, Tan ZJ, Chen J, et al. Cyclovirobuxine D inhibits cell proliferation and induces mitochondria-mediated apoptosis in human gastric cancer cells[J]. Molecules, 2015, 20(11): 20659-20668.
[10]Jiang FQ, Chen YD, Ren S, et al. Cyclovirobuxine D inhibits colorectal cancer tumorigenesis via the CTHRC1-AKT/ERK-Snail signaling pathway[J]. Int J Oncol, 2020, 57(1): 183-196.
[11]Zhang JW, Chen YD, Lin J, et al. Cyclovirobuxine D exerts anticancer effects by suppressing the EGFR-FAK-AKT/ERK1/2-Slug signaling pathway in human hepatocellular carcinoma[J]. DNA Cell Biol, 2020, 39(3): 355-367.
[12]Zhou LQ, Tang H, Wang F, et al. Cyclovirobuxine D inhibits cell proliferation and migration and induces apoptosis in human glioblastoma multiforme and low-grade glioma[J]. Oncol Rep, 2020, 43(3): 807-816.
[13]Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects[J]. FASEB J, 2005, 19(3): 311-330.
[14]Large DE, Abdelmessih RG, Fink EA, et al. Liposome composition in drug delivery design, synthesis, characterization, and clinical application[J]. Adv Drug Deliv Rev, 2021, 176: 113851.
[15]邓晓冬. 环维黄杨星D脂质体的制备与质量研究[D]. 广州中医药大学, 2016.
[16]胡江波, 杨林, 王红, 等. 高效液相色谱法测定环维黄杨星D脂质体的含量[J]. 激光杂志, 2014, 35: 112-113.
[17]陈静, 张景勍, 何丹, 等. 环维黄杨星D磷脂复合物药代动力学评价[J]. 第二军医大学学报, 2016, 37: 17-21.
[18]Wei HM, Liu T, Jiang N, et al. A novel delivery system of Cyclovirobuxine D for brain targeting: Angiopep-conjugated Polysorbate 80-coated liposomes via intranasal administration[J].J Biomed Nanotechnol, 2018, 14(7): 1252-1262.
[19]Touitou E, Dayan N, Bergelson L, et al. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties[J]. J Control Release, 2000, 65(3), 403-418.
[20]李理宇, 王洪权. 新型经皮给药载体—醇质体的研究进展[J]. 中国新药杂志 2010, 19(1): 33-38.
[21]于洋, 周莉玲, 刘新国. 环维黄杨星D醇质体体外经皮渗透性研究[J]. 广州中医药大学学报 2010, 27(3): 279-281.
[22]于洋, 周莉玲, 李秀梅. 正交实验优化环维黄杨星D醇质体凝胶贴剂的制备研究[J]. 时珍国医国药 2010, 21(2): 402-403.
[23]De JongWH, Borm PJ. Drug delivery and nanoparticles: Applications and hazards[J]. Int J Nanomedicine, 2008, 3(2): 133-149.
[24]Wei HM, Lai SS, Wei JB, et al. A novel delivery method of Cyclovirobuxine D for brain-targeting: Chitosan coated nanoparticles loading Cyclovirobuxine D by intranasal administration[J].J Nanosci Nanotechnol, 2018, 18(8): 5274-5282.
[25]Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs[J]. Int J Pharm, 1994, 106(1): 151.
[26]Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharaceutical aspects[J]. Pharm Res, 1995, 12(11): 15611.
[27]李兆明, 陈智, 于峰, 等. 自微乳制剂的研究进展[J]. 齐鲁药事, 2009, 128(12): 98-100.
[28]Ke ZC, Hou XF, Jia XB. Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of Cyclovirobuxine D[J]. Drug Des Devel Ther, 2016, 10: 2049-2060.
[29]陈淑奎. 环维黄杨星D固态自微乳处方研究及伏立康唑注射剂药代动力学初步研究[D]. 华中科技大学, 2012.

相似文献/References: